Within its last year performance, OVID rose by 7.02%, with highs and lows ranging from $4.14 to $2.40, whereas the simple moving average fell by -12.02% in the last 200 days.
On December 21, 2023, BTIG Research started tracking Ovid Therapeutics Inc (NASDAQ: OVID) recommending Buy. A report published by Oppenheimer on October 13, 2023, Initiated its previous ‘Outperform’ rating for OVID. Cantor Fitzgerald also Downgraded OVID shares as ‘Neutral’, setting a target price of $4 on the company’s shares in a report dated April 20, 2021. JMP Securities December 02, 2020d its ‘Mkt Outperform’ rating to ‘Mkt Perform’ for OVID, as published in its report on December 02, 2020. Citigroup’s report from December 02, 2020 suggests a price prediction of $4 for OVID shares, giving the stock a ‘Neutral’ rating. RBC Capital Mkts also rated the stock as ‘Outperform’.
Analysis of Ovid Therapeutics Inc (OVID)
Further, the quarter-over-quarter increase in sales is 205.88%, showing a positive trend in the upcoming months.
One of the most important indicators of Ovid Therapeutics Inc’s future performance is equity, which can be evaluated using several well-rounded types of analysis and research techniques. The goal here is to ensure that your current return on equity of -47.57% is sufficient for you to turn a profit off your investment. Taking into account the quick ratio of the company, currently set at 9.55, you can see that the company can cover any debts it may have, which can easily be seen in the annual report of the company.
For any stock, average volume can also provide valuable insight into volatility, and OVID is recording 209.60K average volume. Furthermore, long-term investors anticipate a median target price of $8.00, showing growth from the present price of $3.05, which can serve as yet another indication of whether OVID is worth investing in or should be passed over.
How Do You Analyze Ovid Therapeutics Inc Shares?
Along with the fundamentals, it is also important to consider how many employees own shares of the company. This is because the values should be in line with investors’ expectations. As such, the current holdings of company stock inside the company are set at 17.19%. This can enable you to see the extent to which executives own the company’s stock. As opposed to executive stock, institutional ownership accounts for 63.68% of the company’s shares, contributing to an indication of company value, since large shareholders may signify strength within the organization.
OVID shares are owned by institutional investors to the tune of 63.68% at present.
